Printer Friendly

NABIL HANNA PROMOTED TO SENIOR VICE PRESIDENT, RESEARCH AND PRECLINCIAL DEVELOPMENT AT IDEC PHARMACEUTICALS

 SAN DIEGO, Aug. 11 /PRNewswire/ -- IDEC Pharmaceuticals Corp. (NASDAQ: IDPH) today announced that Nabil Hanna, Ph.D., has been promoted to the position of senior vice president, research and preclinical development. He was formerly vice president, research and preclinical development.
 "Dr. Hanna and his research staff have led the expansion of IDEC's technology from first-generation mouse antibodies to genetically engineered chimeric, human and primate antibodies," said William H. Rastetter, Ph.D., president and chief executive officer of IDEC Pharmaceuticals. "The most notable accomplishments under his direction have been the discovery and development of PRIMATIZED(TM) antibodies and of expression systems for producing high levels of antibodies in cell culture. Both of these innovations are providing IDEC with competitive advantages. PRIMATIZED antibodies -- which combine human and macaque monkey components -- expand the potential of antibody therapy beyond acute diseases to chronic conditions. In addition, our proprietary expression systems potentially improve the cost effectiveness of antibody therapies and expand their clinical and commercial application."
 Dr. Hanna, 50, joined IDEC in 1990 from SmithKline Beecham, where he was director of the department of immunology and director of the inflammation and arthritis program. Prior to serving at SmithKline Beecham, he was a lead scientist at the National Cancer Institute- Frederick Cancer Research Center. He has published extensively in the areas of inflammation research and therapy of cancer metastases and autoimmune diseases.
 IDEC Pharmaceuticals is focused on the development of targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company's most advanced product candidates include pan-B antibodies to treat B-cell lymphomas, MELIMMUNE(TM) antibodies to treat malignant melanoma, as well as a PRIMATIZED anti-CD4 antibody recently cleared by the FDA for clinical testing in rheumatoid arthritis patients. These agents typically are designed to act through immune system mechanisms and potentially offer greater specificity of action, longer therapeutic effect and lower toxicity than is typical of existing therapies. They also can be administered in outpatient settings, providing the opportunity to reduce overall treatment costs.
 IDEC Pharmaceuticals is located at 11011 Torreyana Road, San Diego, CA 92121.
 -0- 8/11/93
 /CONTACT: Richard W. Krawiec, Director, Investor Relations and Corporate Communications, or William H. Rastetter, President and CEO of IDEC Pharmaceuticals, 619-550-8656/
 (IDPH)


CO: IDEC Pharmaceuticals Corp. ST: California IN: MTC SU: PER

EH-JB -- SD003 -- 1692 08/11/93 12:36 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 11, 1993
Words:386
Previous Article:CHESTER VALLEY BANCORP INC. ANNOUNCES RECORD EARNINGS FOR ITS FISCAL 1993 YEAR END
Next Article:FAIR, ISAAC DECLARES DIVIDEND
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters